@article{852d4f11e1054b9eb5b9abbe0834657e,
title = "Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy",
abstract = "Population sequencing was performed for persons identified with persistent low-level viremia in 2 clinical trials. Persistent low-level viremia (defined as plasma HIV-1 RNA level >50 and <1000 copies/mL in at least 2 determinations over a 24-week period, after at least 24 weeks of antiretroviral therapy) was observed in 65 (5.6%) of 1158 patients at risk. New resistance mutations were detected during persistent low-level viremia in 37% of the 54 evaluable cases. The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3). Detection of new mutations was associated with higher HIV-1 RNA levels during persistent low-level viremia.",
author = "Babafemi Taiwo and Sebastien Gallien and Evgenia Aga and Heather Ribaudo and Richard Haubrich and Kuritzkes, {Daniel R.} and Eron, {Joseph J.}",
note = "Funding Information: This work was supported by the {\textquoteleft}{\textquoteleft}Agence Nationale de Recherche sur le SIDA{\textquoteright}{\textquoteright} Fellowship Grant for Post-Graduate Studies (to S. G.), National Institutes of Health (K24-AI064086 to R.H.), UCSD Center for AIDS Research (AI36214 to R. H.), UCSD ACTU (AI69432 to R. H.), National Institutes of Health (K24 RR061482 to D. K.), ACTG Virology Support Laboratory (U01 AI 068636 to D. K.), ACTU (AI69423 to J. J. E.), UNC Center for AIDS Research (AI50410 to J. J. E.), CTSA (RR025747 to J. J. E.), and Statistical and Data Management Center of the AIDS Clinical Trials Group, under the National Institute of Allergy and Infectious Diseases (1 U01 AI068634 to H. J. R. and E. A.)",
year = "2011",
month = aug,
day = "15",
doi = "10.1093/infdis/jir353",
language = "English (US)",
volume = "204",
pages = "515--520",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",
}
